SCHD Now Concentrates 42 Percent of Your Money in Just 10 Stocks. Here Is Who Should Still Own It

Most Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) owners assume they are buying broad market diversification. The latest Schwab fact sheet tells a different story. SCHD’s top 10 holdings now account for 41% of the fund’s $71.6 billion in net assets, well above the roughly 30% top-10 weight typical of large-cap dividend peers. SCHD still earns its reputation as a low-cost income workhorse, but the concentration question changes who should treat it as a core holding versus a sleeve.

What SCHD is built to do

SCHD tracks the Dow Jones U.S. Dividend 100 Index, which screens for cash flow to debt, return on equity, dividend yield, and five-year dividend growth, then reconstitutes once a year. The screen is the point. It filters out high yielders that cannot sustain payouts and tilts the portfolio toward established cash generators. The return engine is plain. You get dividends from roughly 100 quality-screened companies plus whatever capital appreciation those businesses produce. No options overlay, no leverage, no derivatives.

The expense ratio of 0.06% puts SCHD in the cheapest tier of any dividend ETF, and the trailing yield sits near 3.9% based on recent quarterly distributions, well above the S&P 500’s roughly 1.3%.

Does the strategy deliver?

SCHD’s price returned 26% over the past year and 19% year to date through early June. The five-year price gain of 50% trails the S&P 500’s roughly 90% over the same window, which is the honest tradeoff: the dividend-quality screen kept SCHD out of the mega-cap tech names that drove most of the index’s gains. Add a decade of compounded dividends to the 229% ten-year price gain and the absolute result still works for income investors.

The top holdings explain the recent rebound. ConocoPhillips (NYSE:COP | COP Price Prediction) is up 29% year to date, Chevron (NYSE:CVX) is up 27%, and Altria (NYSE:MO) is up 26%. Altria’s 5.8% yield and Bristol-Myers Squibb’s 4.4% yield are doing exactly what the strategy promises.

The concentration tradeoff

The 42% top-10 weight is not random. It is a byproduct of the yield-and-quality screen plus annual reconstitution. The fund holds essentially no real estate or utilities and tilts heavily toward energy, healthcare, and consumer staples. The top tier sits in a narrow band, with Bristol-Myers Squibb at 4% down to Coca-Cola (KO) and Altria at 4% each.

Three risks matter for a holder. A single-sector shock such as an oil-price collapse or a tobacco regulatory event hits the fund harder than its 100-stock roster suggests. The absence of meaningful tech exposure means SCHD will continue lagging in markets driven by AI and semiconductors. And annual reconstitution can swap out names in size, which generates tax events for non-IRA holders.

Who SCHD still fits

SCHD works as a dividend-growth core for accumulators reinvesting distributions and for retirees who want a rising income stream paired with rock-bottom fees. The $0.26 Q1 2026 distribution is roughly double the $0.12 paid in late 2011, which is the kind of payout growth income investors need against inflation. AbbVie (NYSE:ABBV) and the rest of the top tier kicked in 2.97% yields plus growth.

Investors who already own a total-market or S&P 500 fund can pair SCHD with it cleanly because the dividend screen excludes most of the mega-cap growth names that dominate broad benchmarks. Investors whose entire equity allocation sits in SCHD should add a broad growth or international dividend fund to offset the energy and staples tilt. Treat SCHD as a high-quality income sleeve that happens to concentrate its bets, and it earns its place. Mistake it for a diversified core, and the next sector drawdown will cost more than the dividend pays.